INDICATIONS AND USAGE Osimertinib (Osimert) is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy.
DOSAGE AND ADMINISTRATION Recommended Dosage Regimen The recommended dose of Osimertinib (Osimert) is 80 mg tablet once a day until disease progression or unacceptable toxicity. Osimertinib (Osimert) can be taken with or without food, If a dose of Osimertinib (Osimert) is missed, do not make up the missed dose and take the next dose as scheduled.
Tyrosine kinase inhibitor
multi-target kinase inhibitor
Tyrosine kinase inhibitor
polymerase (PARP) inhibitor
Tyrosin Kinase Inhibitor (TKI)
Androgen receptor inhibitors
Mezoxia
fluoropyrimidines
Tyrosine kinase inhibitor
Tyrosine kinase inhibitor
